急性冠状动脉综合征患者应用依折麦布和阿托伐他汀联合治疗的临床疗效及对主要心血管不良事件发生率的影响

YANG Ru-ping

doi:10.3969/j.issn.1009-8933.2025.04.007

摘要：Background Acute coronary syndrome(ACS)is a cardiovascular emergency with which patients continue to face a considerable long-term risk of major adverse cardiovascular events(MACE)even after receiving standard treatment.Intensive lipid-lowering therapy is central to the secondary prevention of ACS;However,some patients fail to achieve lipid targets or are intolerant to statin monotherapy.A dual lipid-lowering strategy combining ezeti-mibe with statins has demonstrated advantages in the management of various dyslipidemias,yet its clinical efficacy and impact on long-term cardiovascular outcomes in ACS patients require further substantiation.Methods A total of 60 ACS patients treated at our hospital from June 2023 to November 2024 were enrolled in this study.They were randomly assigned using a random number table method into two groups:the observation group(n=30,receiving ezetimibe plus atorvastatin)and the control group(n=30,receiving atorvastatin monotherapy).Lipid profiles[in-cluding low density lipoprotein cholesterol(LDL C),total cholesterol(TC),and triglycerides(TG)]and serum in-flammatory markers[high sensitivity C reactive protein(hs CRP)and interleukin 6(IL 6)]were assessed before and after treatment in both groups.Additionally,the occurrence of MACE during the treatment period was recorded and analyzed.Results After treatment,there was no significant difference in TG levels and the occurrence of adverse reactions mainly between the two groups(P>0.05).The observation group showed significantly lower levels of TC,LDL C,hs CRP,and IL 6 compared to the control group(P<0.05).There was no significant difference in the inci-dence of adverse reactions between the two groups after treatment(P>0.05).Kaplan-Meier survival analysis dem-onstrated that the incidence of MACE was significantly lower in the observation group compared to the control group(Log rank χ²=4.667,P=0.031).Conclusions The combination of ezetimibe and atorvastatin was more ef-fective in lowering lipid and inflammatory levels,demonstrated a trend toward reducing the risk of MACE,and did not significantly increase adverse reactions.[S Chin J Cardiol 2025;26(4):267-275]